Role of Iron Chelators in Mucormycosis.
作者信息
Mahalmani Vidya, Sarma Phulen, Prakash Ajay, Medhi Bikash
机构信息
Department of Pharmacology, Jawaharlal Nehru Medical College, Kaher, Belagavi, Karnataka, India.
Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
出版信息
Indian J Pharmacol. 2021 Jul-Aug;53(4):261-263. doi: 10.4103/ijp.ijp_604_21.
Abstract
摘要
相似文献
1
Role of Iron Chelators in Mucormycosis.
Indian J Pharmacol. 2021 Jul-Aug;53(4):261-263. doi: 10.4103/ijp.ijp_604_21.
2
COVID-19 associated mucormycosis, host-iron assimilation: Probiotics can be a novel therapy.
Indian J Pharmacol. 2021 Sep-Oct;53(5):415-416. doi: 10.4103/ijp.ijp_406_21.
3
Lactoferrin, a potential iron-chelator as an adjunct treatment for mucormycosis - A comprehensive review.
Int J Biol Macromol. 2021 Sep 30;187:988-998. doi: 10.1016/j.ijbiomac.2021.07.156. Epub 2021 Jul 27.
4
The iron chelator deferasirox protects mice from mucormycosis through iron starvation.
J Clin Invest. 2007 Sep;117(9):2649-57. doi: 10.1172/JCI32338.
5
Survival in rhinocerebral mucormycosis: is iron the key?
Neurol India. 2007 Oct-Dec;55(4):416. doi: 10.4103/0028-3886.37101.
6
[Iron and invasive fungal infection].
Rev Iberoam Micol. 2013 Oct-Dec;30(4):217-25. doi: 10.1016/j.riam.2013.04.002. Epub 2013 May 14.
7
Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.
Kidney Int. 1994 Mar;45(3):667-71. doi: 10.1038/ki.1994.89.
8
Should statins be considered for the management of mucormycosis in COVID-19?
Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102162. doi: 10.1016/j.dsx.2021.05.035. Epub 2021 Jun 5.
9
Mucormycosis in COVID-19 recovered patients.
J Med Virol. 2022 Apr;94(4):1272-1273. doi: 10.1002/jmv.27522. Epub 2021 Dec 18.
10
Palatal mucormycosis in a patient with SARS-CoV-2 infection.
CMAJ. 2021 Aug 16;193(32):E1254. doi: 10.1503/cmaj.211026.
引用本文的文献
1
Role of the putative gene in normal germination of spores and virulence of the .
Microb Cell. 2025 Aug 12;12:195-209. doi: 10.15698/mic2025.08.856. eCollection 2025.
2
Investigating the Hepcidin Gene Polymorphisms in COVID-19-Associated Mucormycosis Susceptibility: A Clinical-Laboratory Study.
Iran J Med Sci. 2024 Jul 1;49(7):450-460. doi: 10.30476/ijms.2023.99589.3167. eCollection 2024 Jul.
3
Rise of mucormycosis during the COVID-19 pandemic and the challenges faced.
Curr Med Mycol. 2023 Mar;9(1):44-55. doi: 10.18502/cmm.2023.345032.1400.
4
Coping With Stress: The Mitokine GDF-15 as a Biomarker of COVID-19 Severity.
Front Immunol. 2022 Feb 16;13:820350. doi: 10.3389/fimmu.2022.820350. eCollection 2022.
5
Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach.
J Infect Public Health. 2022 Apr;15(4):466-479. doi: 10.1016/j.jiph.2022.02.007. Epub 2022 Feb 18.
6
COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis.
3 Biotech. 2022 Jan;12(1):6. doi: 10.1007/s13205-021-03080-4. Epub 2021 Dec 6.
7
Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis.
J Crit Care. 2022 Feb;67:172-181. doi: 10.1016/j.jcrc.2021.09.023. Epub 2021 Nov 20.
本文引用的文献
1
Mucormycosis with orbital compartment syndrome in a patient with COVID-19.
Am J Emerg Med. 2021 Apr;42:264.e5-264.e8. doi: 10.1016/j.ajem.2020.09.032. Epub 2020 Sep 16.
2
Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective.
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):971-978. doi: 10.1016/j.dsx.2020.06.054. Epub 2020 Jun 27.
3
Invasive and Non-Invasive Fungal Rhinosinusitis-A Review and Update of the Evidence.
Medicina (Kaunas). 2019 Jun 28;55(7):319. doi: 10.3390/medicina55070319.
4
Mucormycosis: Battle with the Deadly Enemy over a Five-Year Period in India.
J Fungi (Basel). 2018 Apr 6;4(2):46. doi: 10.3390/jof4020046.
5
A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007).
Clin Infect Dis. 2012 Feb;54 Suppl 1:S35-43. doi: 10.1093/cid/cir880.
6
Meeting the challenges of an emerging pathogen: the Henry Schueler 41&9 Foundation International Forum on Mucormycosis.
Clin Infect Dis. 2012 Feb;54 Suppl 1:S1-4. doi: 10.1093/cid/cir862.
7
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.
J Antimicrob Chemother. 2012 Mar;67(3):715-22. doi: 10.1093/jac/dkr375. Epub 2011 Sep 20.
8
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007.
Clin Microbiol Infect. 2011 Dec;17(12):1859-67. doi: 10.1111/j.1469-0691.2010.03456.x. Epub 2011 Jul 1.
9
Forty-one recent cases of invasive zygomycosis from a global clinical registry.
J Antimicrob Chemother. 2010 Feb;65(2):296-302. doi: 10.1093/jac/dkp430. Epub 2009 Dec 11.
10
Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis.
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9367-72. doi: 10.1073/pnas.0709578105. Epub 2008 Jun 26.
Zotero 插件